Molecular imaging method for evaluating liver regeneration capacity after ALPPS operation
US11123033B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 30, 2020 |
| Grant date | Sep 21, 2021 |
| Priority date | — |
| Expiry date | Sep 30, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61B2017/00778
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a molecular imaging method for evaluating liver regeneration ability after ALPPS. The method includes steps of: 1) preparing a VX2 rabbit liver cancer model; 2) performing ALPPS for the VX2 rabbit liver cancer model; 3) synthesizing 18F-Fluoromethylcholine (18F-Methylcholine, 18F-FCH); 4) PET/CT imaging and data processing for 18F-FCH. The disclosure is the first to propose the use of 18F-FCH PET/CT to monitor the proliferative capacity of residual liver, and further indirectly reflect the increased ability of cell membrane synthesis on the basis that 18F-FCH has higher choline metabolism in residual liver tissue, so that the liver regeneration ability after ALPPS is evaluated by the molecular imaging method, thereby providing important new ideas for the clinical selection of ALPPS to choose the best time for second-stage surgery.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.